Bariatric and gastrointestinal medical device firm Apollo Endosurgery Inc. has won FDA authorization to terminate its Lap-band lower BMI (LBMI) post-approval study due to long-term data on safety and effectiveness in already published evidence. LBMI's early termination will amount to about $5.1 million in savings for the company, expected over the length of the research. The study was anticipated to enroll as many as 325 patients at 20 sites; 181 patients had since the end of 2017 been enrolled at 13 clinical sites.